Atara immunotherapy for mesothelioma promising

You are here: Home > Biotech > Current Article

By Staff Report / Wednesday, June 5th, 2019 / Comments Off on Atara immunotherapy for mesothelioma promising

New data presented by Memorial Sloan Kettering at the American Society of Clinical Oncology in Chicago June 4 showed promising results for mesothelioma patients with solid tumors who were given a new immunotherapy from Atara Biotherapeutics. The CAR T therapy targeting mesothelin was delivered along with chemotherapy. The results ”reaffirm mesothelin as a promising target…

This article is only available to Business Times subscribers

Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
Check the STATUS of your Subscription Account.